Home › Trials › NCT07091617

Digital chatbot program for inherited cancer genetic testing in young adults

AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients

Not applicable Interventional Alliance for Clinical Trials in Oncology · NCT07091617

This study tests whether a chatbot-based digital program helps young adults with cancer (ages 18–39) get genetic counseling and testing more often than standard remote genetic services.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment535 (estimated)
Ages18 Years and up
SexAll
SponsorAlliance for Clinical Trials in Oncology Academic / other
Locations231 sites (Anchorage, Alaska and 230 other locations)
Trial IDNCT07091617 on ClinicalTrials.gov

What this trial studies

Young adults ages 18–39 with a history of cancer are randomized to either standard telehealth genetic counseling or an enhanced eHealth program that uses the Genetic Journey chatbot for pre-test education, with genetic testing and result disclosure conducted remotely. The primary goals are to see if the chatbot increases uptake of genetic counseling and uptake of genetic testing. Secondary aims compare short-term and long-term cognitive (knowledge), affective (distress), behavioral (screening and family communication) outcomes, and costs to determine non-inferiority. Exploratory analyses will examine moderators of uptake and outcomes and identify barriers and facilitators to implementing the digital delivery model.

Who should consider this trial

Good fit: Ideal candidates are adolescents and young adults aged 18–39 with any current or past cancer diagnosis who can read and speak English or Spanish and do not have cognitive impairment.

Not a fit: Patients who cannot use English or Spanish, have impaired decision-making capacity, or strongly prefer in-person counseling may not benefit from the digital-first approach.

Why it matters

Potential benefit: If successful, the chatbot model could increase access to genetic counseling and testing for young cancer patients while reducing provider time and program costs.

How similar studies have performed: Telehealth genetic services have improved access in prior work and early digital/chatbot interventions show promise, but randomized evidence in adolescents and young adults is limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
* PATIENTS: Age ≥ 18 years and ≤ 39 years at the time of enrollment
* PATIENTS: AYA cancer patients and survivors. This includes patients at any stage of diagnosis (e.g., newly diagnosed, in treatment, in survivorship) and a cancer diagnosis (including pediatric cancers) at any age ≤ 39 years old. Given targeted therapies for BRCA+ and microsatellite instability (MSI)-high/Lynch Syndrome patients and benefit to relatives, patients with metastatic cancer are included. Any history of cancer, regardless of being in treatment or not
* PATIENTS: Language: In order to complete the mandatory patient-completed measures and receive genetic education and counseling, participants must be able to speak and read English or Spanish
* PATIENTS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members
* PATIENTS: No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
* PATIENTS: Participants must meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing assessment provided by Penn Telegenetics by the Eligibility Verification Assessment (EVA) chatbot, or paper forms and genetic counselor's review
* NON-PATIENT PARTICIPANT: Non-patient participants eligible for this study include: oncology providers, members of the care team and clinic staff, genetic counselors, and insurers (i.e., people who work in financial services and/or for insurance companies) who participate in oncology care among AYA in community for this study
* NON-PATIENT PARTICIPANT: Age ≥ 18 years
* NON-PATIENT PARTICIPANT: Non-patient participants must be able to speak and read English or Spanish in order to participate in the key informant interviews

Where this trial is running

Anchorage, Alaska and 230 other locations

+181 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Miscellaneous Neoplasm, NosNon-Neoplastic Condition, Nos
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.